Table 1 Demographic, clinical, histological, molecular and treatment characteristics of all patients (n = 400) and analysis of groups homogeneity (Pearson Chi²-test)

Age

   < 40

76 (30.5%)

25 (16.6%)

0.001

   ≥ 40

173 (69.5%)

122 (83.4%)

Menopausal status

   No

178 (71.5%)

85 (56.3%)

0.008

   Yes

60 (24.1%)

56 (37.1%)

   Unknown

11 (4.4%)

10 (6.6%)

Side

   Right

128 (51.4%)

72 (47.7%)

0.552

   Left

120 (48.2%)

79 (52.2%)

   Bilateral

1 (0.4%)

0

Surgery

   Mastectomy

209 (83.9%)

130 (86.1%)

0.561

   BCT

40 (16.1%)

21 (13.9%)

Histology

   DIC

231 (92.8%)

136 (90.1%)

0.248

   LIC

12 (4.8%)

13 (8.6%)

   Other

1

0

   Unknown

5 (2%)

2 (1.3%)

SBR

   I

15 (6%)

12 (7.9%)

0.72

   II

153 (61.4%)

97 (64.2%)

   III

74 (29.7%)

38 (25.2%)

   Unknown

7 (2.8%)

4 (2.6%)

Hormonal Receptor

   ER+/PR+

123 (49.4%)

84 (55.6%)

0.205

   ER+/PR-

31 (12.4%)

25 (16.6%)

   ER-/PR+

25 (10%)

12 (7.9%)

   ER-/PR-

65 (26.1%)

28 (18.5%)

   Unknown

5 (2%)

2 (1.3%)

Tumour

   pT1

28 (11.2%)

21 (13.9%)

0.867

   pT2

142 (57%)

84 (55.6%)

   pT3

63 (25.3%)

35 (23.2%)

   pT4

12 (4.8%)

7 (4.6%)

   Unknown

4 (1.6%)

4 (2.6%)

pN, axillary

   pN0

44 (17.7%)

42 (27.8%)

0.009

   pN1

69 (27.7%)

46 (30.5%)

   pN2

77 (30.9%)

47 (31.1%)

   pN3

50 (20.1%)

13 (8.6%)

   Unknown

9 (3.6%)

3 (2%)

Number of cycle of CT delivered with RT

   1

87 (34.9%)

25 (16.6%)

< 0.001

   ≥ 2

162 (65.1%)

126 (83.4%)

Breast/thoracic wall irradiation

   No

2 (0.8%)

12 (7.9%)

< 0.001

   Yes

247 (99.2%)

139 (92.1%)

Prophylactic supraclavicular fossa radiotherapy

   No

17 (6.8%)

10 (6.6%)

0.556

   Yes

232 (93.2%)

141 (93.4%)

Internal mammary radiotherapy

   No

16 (6.4%)

9 (6%)

0.517

   Yes

233 (93.6%)

142 (94%)

Axillary radiotherapy

   No

220 (88.4%)

120 (79.5%)

0.012

   Yes

29 (11.6%)

31 (20.5%)